Impaired proliferative response and low interleukin-2 production in patients with lymphoma.
1. The proliferative response of phytohemagglutinin-activated lymphocytes from patients with Hodgkin's and non-Hodgkin's lymphoma was compared to their interleukin-2 (IL-2) production. 2. Impairment in the lymphoproliferative response paralleled a reduction in IL-2 production. 3. Suppressor cells and serum factors which depressed the proliferative response of the patients' lymphocytes inhibited IL-2 production. 4. Enhanced prostaglandin synthesis was one of the factors causing impairment of the proliferative response and the diminished IL-2 production in lymphocytes from patients with lymphoma. 5. A partial restoration of patients' cellular responses in vitro was achieved by adding conditioned media containing IL-1 or IL-2.
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D007108:Immune Tolerance; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007376:Interleukin-2 / Q000096:biosynthesis*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
D007106:Immune Sera; D007376:Interleukin-2; D010835:Phytohemagglutinins; D007213:Indomethacin